Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after ... amid rising demand for its Zepbound and Mounjaro obesity drugs. On Wednesday, Novo ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

The stock has more than doubled in value in the last two years, making it the most valuable health care company ... $4.27 billion for Mounjaro, according to LSEG data. Lilly has previously ...

Eli Lilly expects 2024 revenue to be $45 billion, with Mounjaro and Zepbound sales contributing ... GLP-1 diabetes sales increased by 12%, and Obesity care sales increased by 91%.